NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/15/2024
Back to search
Official data from USPTO
NERVIANO MEDICAL SCIENCES PART OF NMS GROUP
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NERVIANO MEDICAL SCIENCES PART OF NMS GROUP
ST13
US500000079326491Class
5, 41, 42
Filing
79326491
Registration
6993809
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
11/15/2024
Trademark type
Word
Nice classes
5, 41, 42
Filing date
07/09/2021
Registration date
03/07/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/07/2023
Last transaction
03/07/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
16
Owner location
IT
Examiner
STURMAN, MELISSA
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
NERVIANO MEDICAL SCIENCES S.R.L.
Representatives
Jeffrey B. Sladkus, Esq. The Sladkus Law Group
Technical classification
Nice Classes
Class 5Class 41Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and veterinary preparations for treating cancermyocardium infarction and malaria; sanitary preparations for medical purposes; biological preparations for medical purposes for the treatment of cancermyocardium infarction and malaria; chemical preparations for pharmaceutical purposesfor the treatment of cancermyocardium infarction and malaria; chemico-pharmaceutical preparations for the treatment of cancermyocardium infarction and malaria; diagnostic preparations for medical purposes; pharmaceutical preparations for the treatment of cancermyocardium infarction and malaria; pharmaceuticals in the nature of anti-cancer preparations
Class 41
Educationproviding classescoursesseminarsworkshopsrelated to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field; providing of training related to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field; providing entertainment in the nature of exhibitionslive showsonline non-downloadable video and non-downloadable films via video-on-demand transmission servicesrelated to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field; educational servicesproviding know-how transfer training related to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field; providing online electronic publicationsnot downloadablein the nature of booksmagazinesnewsletters related to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field; publication of textsother than publicity textsrelated to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field; arranging and conducting of conferencescongresses and symposium related to research and developmenttestingmanufacturing and marketing in the geneticmedical and pharmaceutical field
Class 42
Scientifictechnologicalanalysis and research servicesscientific research and development in the field of medicinetesting in the field of pharmaceuticals and gene-based drugs and therapies; biological research in the field of medicinetesting in the field of pharmaceuticals and gene-based drugs and therapies; chemical research in the field of medicinetesting in the field of pharmaceuticals and gene-based drugs and therapies; medical and scientific researchconducting clinical trials for others in the field of medicinetesting in the field of pharmaceuticals and gene-based drugs and therapies; quality control for others in the field of medicinetesting in the field of pharmaceuticals and gene-based drugs and therapies
Publications
History of USPTO decisions and trademark events.
35 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/10/2023
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
06/11/2023
XXCR
GENERIC MADRID TRANSACTION CREATED
06/11/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/07/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/07/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
03/07/2023
GPNX
NOTIFICATION PROCESSED BY IB
12/21/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/20/2022
PUBO
PUBLISHED FOR OPPOSITION
12/20/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/30/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/30/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/30/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/13/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/27/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/27/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/27/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/12/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/12/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
09/12/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/12/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/12/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/12/2022
RFNT
REFUSAL PROCESSED BY IB
06/22/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/02/2022
RFRR
REFUSAL PROCESSED BY MPU
06/02/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/02/2022
CNRT
NON-FINAL ACTION WRITTEN
06/01/2022
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
05/23/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/13/2022
CNRT
NON-FINAL ACTION WRITTEN
04/12/2022
DOCK
ASSIGNED TO EXAMINER
03/29/2022
MAFR
APPLICATION FILING RECEIPT MAILED
11/30/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/26/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/25/2021
Continuous trademark protection
Get notified about every new filing that threatens NERVIANO MEDICAL SCIENCES PART OF NMS GROUP or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.